Genfit S.A. (EPA:GNFT)
14.00
-0.66 (-4.50%)
Aug 3, 2026, 1:44 PM CET
Genfit Revenue
In the year 2025, Genfit had annual revenue of 71.12M EUR with 0.25% growth. Genfit had revenue of 35.45M in the half year ending December 31, 2025, with 55.46% growth.
Revenue
71.12M
Revenue Growth
+0.25%
P/S Ratio
10.35
Revenue / Employee
440.03K
Employees
161
Market Cap
733.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 71.12M | 177.00K | 0.25% |
| Dec 31, 2024 | 70.94M | 32.76M | 85.83% |
| Dec 31, 2023 | 38.18M | 11.61M | 43.70% |
| Dec 31, 2022 | 26.57M | -59.01M | -68.96% |
| Dec 31, 2021 | 85.58M | 77.82M | 1,003.11% |
| Dec 31, 2020 | 7.76M | -33.20M | -81.06% |
| Dec 31, 2019 | 40.96M | 33.47M | 446.58% |
| Dec 31, 2018 | 7.49M | 639.00K | 9.32% |
| Dec 31, 2017 | 6.86M | 72.00K | 1.06% |
| Dec 31, 2016 | 6.78M | 2.43M | 55.64% |
| Dec 31, 2015 | 4.36M | -2.42M | -35.68% |
| Dec 31, 2014 | 6.78M | 808.40K | 13.55% |
| Dec 31, 2013 | 5.97M | -42.90K | -0.71% |
| Dec 31, 2012 | 6.01M | -768.20K | -11.33% |
| Dec 31, 2011 | 6.78M | 1.73M | 34.35% |
| Dec 31, 2010 | 5.05M | -5.79M | -53.43% |
| Dec 31, 2009 | 10.83M | -9.08M | -45.60% |
| Dec 31, 2008 | 19.91M | -296.57K | -1.47% |
| Dec 31, 2007 | 20.21M | 8.79M | 76.95% |
| Dec 31, 2006 | 11.42M | -1.77M | -13.43% |
| Dec 31, 2005 | 13.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 156.33M |
| Cellectis | 65.14M |
| Nanobiotix | 32.59M |
| MedinCell | 24.28M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
| Sensorion | 5.81M |
Genfit News
- 5 weeks ago - GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma - GlobeNewsWire
- 6 weeks ago - GENFIT: June 15, 2026 Combined Shareholders Meeting Results - GlobeNewsWire
- 7 weeks ago - GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH - GlobeNewsWire
- 2 months ago - Genfit Earnings release: Q1 2026 - Filings
- 3 months ago - Genfit Slides: Investor presentation - Filings
- 4 months ago - Genfit Annual report: Q4 2025 - Filings
- 4 months ago - Genfit Earnings release: Q4 2025 - Filings
- 5 months ago - Genfit Earnings release: Q4 2025 - Filings